Health Care [ 1/12 ] | Pharmaceuticals [ 10/73 ]
NASDAQ | Common Stock
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally.
It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer.
It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F.
Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 7, 25 | -1.87 Decreased by -937.50% | -2.79 Increased by +33.03% |
| Aug 7, 25 | -2.78 Decreased by -1.01 K% | -0.20 Decreased by -1.29 K% |
| May 7, 25 | -0.24 Decreased by -26.53% | -0.19 Decreased by -26.53% |
| Mar 3, 25 | -0.15 Increased by +31.82% | -0.20 Increased by +23.08% |
| Nov 7, 24 | -0.18 Increased by +25.00% | -0.21 Increased by +14.29% |
| Aug 8, 24 | -0.25 Increased by +7.41% | -0.20 Decreased by -25.00% |
| May 9, 24 | -0.19 Increased by +40.63% | -0.19 |
| Mar 4, 24 | -0.22 Increased by +31.25% | -0.21 Decreased by -4.76% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 11.79 M Decreased by -51.13% | -35.52 M Increased by +4.14% | Decreased by -301.29% Decreased by -96.14% |
| Jun 30, 25 | 11.18 M Decreased by -52.42% | -41.59 M Increased by +20.57% | Decreased by -372.20% Decreased by -66.96% |
| Mar 31, 25 | 10.46 M Decreased by -51.66% | -50.88 M Decreased by -38.26% | Decreased by -486.44% Decreased by -186.02% |
| Dec 31, 24 | 29.18 M Increased by +22.15% | 7.26 M Increased by +117.26% | Increased by +24.89% Increased by +114.13% |
| Sep 30, 24 | 24.12 M Decreased by -0.08% | -37.06 M Increased by +19.15% | Decreased by -153.61% Increased by +19.09% |
| Jun 30, 24 | 23.49 M Increased by +14.59% | -52.36 M Decreased by -2.43% | Decreased by -222.93% Increased by +10.61% |
| Mar 31, 24 | 21.64 M Increased by +0.21% | -36.80 M Increased by +73.14% | Decreased by -170.07% Increased by +73.20% |
| Dec 31, 23 | 23.89 M Increased by +8.45% | -42.08 M Increased by +29.50% | Decreased by -176.17% Increased by +35.00% |